[
  {
    "ts": "2025-11-03T13:30:00+00:00",
    "headline": "Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.",
    "url": "https://finance.yahoo.com/news/lilly-plans-build-3-billion-133000644.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e5b10a73-ba23-36d8-9613-67d3afe02895",
      "content": {
        "id": "e5b10a73-ba23-36d8-9613-67d3afe02895",
        "contentType": "STORY",
        "title": "Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.",
        "pubDate": "2025-11-03T13:30:00Z",
        "displayTime": "2025-11-03T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/e9965c6e3eae765dcd3f40e7006f582c",
          "originalWidth": 400,
          "originalHeight": 200,
          "caption": "SOURCE: Eli Lilly and Company",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/36UMxvUr1pObp.6k8.iqvw--~B/aD0yMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e9965c6e3eae765dcd3f40e7006f582c.cf.webp",
              "width": 400,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qP3YFPzYilHCyDw.YjDX2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e9965c6e3eae765dcd3f40e7006f582c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-plans-build-3-billion-133000644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-plans-build-3-billion-133000644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T13:28:00+00:00",
    "headline": "2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon",
    "summary": "The healthcare industry is chock-full of opportunities for long-term investors.",
    "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-individual-investors-with/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c6c5ab1f-b117-3285-89ef-f1d5ee36aa16",
      "content": {
        "id": "c6c5ab1f-b117-3285-89ef-f1d5ee36aa16",
        "contentType": "STORY",
        "title": "2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon",
        "description": "",
        "summary": "The healthcare industry is chock-full of opportunities for long-term investors.",
        "pubDate": "2025-11-03T13:28:00Z",
        "displayTime": "2025-11-03T13:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1205b8606ff2f707949aa52ff195feca",
          "originalWidth": 2121,
          "originalHeight": 1414,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y5wxEnL9Lw1kdclP7rllJQ--~B/aD0xNDE0O3c9MjEyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/1205b8606ff2f707949aa52ff195feca.cf.webp",
              "width": 2121,
              "height": 1414,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u3YHMHsoo93p.zrpJLAK7A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1205b8606ff2f707949aa52ff195feca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-individual-investors-with/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-healthcare-stocks-individual-investors-132800558.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ISRG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T09:45:00+00:00",
    "headline": "Prediction: The Next Eli Lilly Might Already Be Trading Under $50",
    "summary": "Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.",
    "url": "https://www.fool.com/investing/2025/11/03/prediction-the-next-eli-lilly-might-already-be-tra/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "8350f6ce-a951-3f34-8b36-bfabdc3741f3",
      "content": {
        "id": "8350f6ce-a951-3f34-8b36-bfabdc3741f3",
        "contentType": "STORY",
        "title": "Prediction: The Next Eli Lilly Might Already Be Trading Under $50",
        "description": "",
        "summary": "Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.",
        "pubDate": "2025-11-03T09:45:00Z",
        "displayTime": "2025-11-03T09:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2fb45bb40fa377b383d3f06f59f8b275",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Patient self-administering a shot.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/poKiJEjtTvpX5jGSqGjL8Q--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2fb45bb40fa377b383d3f06f59f8b275.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZEu1Qy_qVT7vYnETBwXGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2fb45bb40fa377b383d3f06f59f8b275.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/prediction-the-next-eli-lilly-might-already-be-tra/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-next-eli-lilly-might-094500387.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T04:06:23+00:00",
    "headline": "Dow Jones Futures Rise; Palantir, Robinhood Earnings Ahead",
    "summary": "The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-palantir-robinhood-amd-lead-earnings/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "62d37222-a461-31e5-bd64-dd1c3cd6bdd9",
      "content": {
        "id": "62d37222-a461-31e5-bd64-dd1c3cd6bdd9",
        "contentType": "STORY",
        "title": "Dow Jones Futures Rise; Palantir, Robinhood Earnings Ahead",
        "description": "",
        "summary": "The stock market has continued to climb, but it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.",
        "pubDate": "2025-11-03T04:06:23Z",
        "displayTime": "2025-11-03T04:06:23Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/62d37222-a461-31e5-bd64-dd1c3cd6bdd9/dow-jones-futures-rise-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/912bce6dcb055a351bef5b1212da1763",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XmT4anXp4OywmZOgwDfXbg--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/912bce6dcb055a351bef5b1212da1763.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wphm8Wz0upbkWRS.vtrO4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/912bce6dcb055a351bef5b1212da1763.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-palantir-robinhood-amd-lead-earnings/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "IBKR"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "ALAB"
            },
            {
              "symbol": "MDB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T03:10:49+00:00",
    "headline": "Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & Company (NYSE:LLY) on October 17 following the exclusion of the company’s oral GLP-1 treatment, orforglipron, from the first group of medications to […]",
    "url": "https://finance.yahoo.com/news/cantor-fitzgerald-reaffirms-price-target-031049882.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d5ee998f-3d1e-37ee-a8e1-15926d66b922",
      "content": {
        "id": "d5ee998f-3d1e-37ee-a8e1-15926d66b922",
        "contentType": "STORY",
        "title": "Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback",
        "description": "",
        "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & Company (NYSE:LLY) on October 17 following the exclusion of the company’s oral GLP-1 treatment, orforglipron, from the first group of medications to […]",
        "pubDate": "2025-11-03T03:10:49Z",
        "displayTime": "2025-11-03T03:10:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23",
          "originalWidth": 283,
          "originalHeight": 178,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8PhkuSOImzcJWO03ORbAAA--~B/aD0xNzg7dz0yODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23.cf.webp",
              "width": 283,
              "height": 178,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LIJLTrtCu6kOCCm8Vfx83Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/324056f0faad680bd4a4c5cc53383c23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-reaffirms-price-target-031049882.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-reaffirms-price-target-031049882.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T22:11:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Eli Lilly, Kimberly-Clark’s deal to buy Kenvue and more in the latest Market Talks covering the Health Care sector.",
    "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-9a3e8e9b?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "fb8af855-13df-3440-9129-8925f7ef71c7",
      "content": {
        "id": "fb8af855-13df-3440-9129-8925f7ef71c7",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Eli Lilly, Kimberly-Clark’s deal to buy Kenvue and more in the latest Market Talks covering the Health Care sector.",
        "pubDate": "2025-11-03T22:11:00Z",
        "displayTime": "2025-11-03T22:11:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/fb8af855-13df-3440-9129-8925f7ef71c7/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/0d1572ee22eead993c208152f7bf0743",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ehl_sx4LG6wiwxnWwAptCw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/0d1572ee22eead993c208152f7bf0743.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HDtYMDFd9x4CSWrhyQ9uig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/0d1572ee22eead993c208152f7bf0743.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/articles/health-care-roundup-market-talk-9a3e8e9b?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T17:03:00+00:00",
    "headline": "Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera",
    "summary": "Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.",
    "url": "https://www.barrons.com/articles/pfizer-trump-drug-prices-novo-nordisk-metsera-0abe8d51?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "cbb104d7-5c93-38e8-8b8a-8075677f9be1",
      "content": {
        "id": "cbb104d7-5c93-38e8-8b8a-8075677f9be1",
        "contentType": "STORY",
        "title": "Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera",
        "description": "",
        "summary": "Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.",
        "pubDate": "2025-11-03T17:03:00Z",
        "displayTime": "2025-11-03T17:03:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cbb104d7-5c93-38e8-8b8a-8075677f9be1/pfizer-aligns-with-trump-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b316512601d6a4a77b9ba30bbac9d200",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fIURyh_GAbgwB5BDIn7bIw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b316512601d6a4a77b9ba30bbac9d200.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/koZJpcM0YDLZkkieBHgKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b316512601d6a4a77b9ba30bbac9d200.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/pfizer-trump-drug-prices-novo-nordisk-metsera-0abe8d51?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:41:00+00:00",
    "headline": "Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?",
    "summary": "NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-q3-earnings-investors-164100391.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a05ebf77-a0f8-3343-a7e4-967953444dd2",
      "content": {
        "id": "a05ebf77-a0f8-3343-a7e4-967953444dd2",
        "contentType": "STORY",
        "title": "Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?",
        "description": "",
        "summary": "NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.",
        "pubDate": "2025-11-03T16:41:00Z",
        "displayTime": "2025-11-03T16:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-q3-earnings-investors-164100391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-q3-earnings-investors-164100391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:13:20+00:00",
    "headline": "Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
    "summary": "The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
    "url": "https://247wallst.com/investing/2025/11/03/viking-therapeutics-could-be-pharmas-next-big-buyout-target/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3e2eb745-2faa-36d9-ac93-8e34c532bb74",
      "content": {
        "id": "3e2eb745-2faa-36d9-ac93-8e34c532bb74",
        "contentType": "STORY",
        "title": "Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
        "description": "",
        "summary": "The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
        "pubDate": "2025-11-03T16:13:20Z",
        "displayTime": "2025-11-03T16:13:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/6464e26647b487fe91e406f103aa3998",
          "originalWidth": 1366,
          "originalHeight": 767,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/euS9UOm2knyrB0G7VM9FLw--~B/aD03Njc7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/6464e26647b487fe91e406f103aa3998.cf.webp",
              "width": 1366,
              "height": 767,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9GqBZFX6mIftCTG_Z_9hDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/6464e26647b487fe91e406f103aa3998.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/03/viking-therapeutics-could-be-pharmas-next-big-buyout-target/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-could-pharma-next-161320501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T15:39:00+00:00",
    "headline": "Phlow Corp. Congratulates the Commonwealth of Virginia and the Virginia Innovation Partnership Corporation on a Historic Investment to Create the Nation’s Largest Workforce Development Center for Advanced Pharmaceutical Manufacturing",
    "summary": "RICHMOND, Va, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), congratulates Governor Glenn Youngkin, the Virginia Innovation Partnership Corporation (VIPC), and several leading Virginia universities on the recent announcement of a $120 million investment from AstraZeneca, Eli Lilly and Company, and Merck to expand Virginia’s life sciences and advanced pharmaceutical manufacturing workforce devel",
    "url": "https://finance.yahoo.com/news/phlow-corp-congratulates-commonwealth-virginia-153900461.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "aa859d9f-6876-39b0-bf12-80428add4a45",
      "content": {
        "id": "aa859d9f-6876-39b0-bf12-80428add4a45",
        "contentType": "STORY",
        "title": "Phlow Corp. Congratulates the Commonwealth of Virginia and the Virginia Innovation Partnership Corporation on a Historic Investment to Create the Nation’s Largest Workforce Development Center for Advanced Pharmaceutical Manufacturing",
        "description": "",
        "summary": "RICHMOND, Va, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), congratulates Governor Glenn Youngkin, the Virginia Innovation Partnership Corporation (VIPC), and several leading Virginia universities on the recent announcement of a $120 million investment from AstraZeneca, Eli Lilly and Company, and Merck to expand Virginia’s life sciences and advanced pharmaceutical manufacturing workforce devel",
        "pubDate": "2025-11-03T15:39:00Z",
        "displayTime": "2025-11-03T15:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/05f06d41819c80d8ce0989b97ee010d9",
          "originalWidth": 6182,
          "originalHeight": 1484,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rWEX_3Lz4Me_IepalaIMeA--~B/aD0xNDg0O3c9NjE4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/05f06d41819c80d8ce0989b97ee010d9.cf.webp",
              "width": 6182,
              "height": 1484,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wq0EGb9FPXcTfEkn6S30Cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/05f06d41819c80d8ce0989b97ee010d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/phlow-corp-congratulates-commonwealth-virginia-153900461.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/phlow-corp-congratulates-commonwealth-virginia-153900461.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T10:00:00+00:00",
    "headline": "Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark",
    "summary": "George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.",
    "url": "https://www.biopharmadive.com/news/tidmarsh-resigns-from-cder-kenvue-to-sell-to-kimberly-clark/804473/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "19e79e3e-1e46-3530-a404-76b5f0daa014",
      "content": {
        "id": "19e79e3e-1e46-3530-a404-76b5f0daa014",
        "contentType": "STORY",
        "title": "Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark",
        "description": "",
        "summary": "George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.",
        "pubDate": "2025-11-03T10:00:00Z",
        "displayTime": "2025-11-03T10:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/tidmarsh-resigns-from-cder-kenvue-to-sell-to-kimberly-clark/804473/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tidmarsh-resigns-cder-kenvue-sell-100000482.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AUPH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]